Receptor-interacting protein kinase-3 (RIPK3) is an activator of necroptotic cell death, but recent work has implicated additional roles for RIPK3 in inflammatory signaling independent of cell death. However, while necroptosis has been shown to contribute to antiviral immunity, death-independent roles for RIPK3 in host defense have not been demonstrated. Using a mouse model of West Nile virus (WNV) encephalitis, we show that RIPK3 restricts WNV pathogenesis independently of cell death. Ripk3 À/À mice exhibited enhanced mortality compared to wildtype (WT) controls, while mice lacking the necroptotic effector MLKL, or both MLKL and caspase-8, were unaffected. The enhanced susceptibility of Ripk3 À/À mice arose from suppressed neuronal chemokine expression and decreased central nervous system (CNS) recruitment of T lymphocytes and inflammatory myeloid cells, while peripheral immunity remained intact. These data identify pleiotropic functions for RIPK3 in the restriction of viral pathogenesis and implicate RIPK3 as a key coordinator of immune responses within the CNS.
INTRODUCTION
Necroptosis is a form of programed cell death coordinated by receptor-interacting protein kinases 1 (RIPK1) and 3 (RIPK3). Stimuli including death receptor and pattern recognition receptor (PRR) ligation induce the activation of RIPK3 and the downstream phosphorylation of mixed lineage kinase domain-like protein (MLKL). MLKL serves as an executioner protein, promoting cell death via plasma membrane disruption and cell rupture (Cho et al., 2009; Wang et al., 2014a) . While the molecular mechanisms that orchestrate necroptosis have been the subject of intense investigation, the physiological relevance of necroptosis during infection and injury is less well defined (Oberst, 2016) . Moreover, recent studies have suggested surprising roles for RIPK1 and RIPK3 in promoting inflammation independently of cell death signaling, indicating that these proteins may serve pleiotropic and context-dependent functions in host immune responses (Lawlor et al., 2015; Moriwaki and Chan, 2016; Najjar et al., 2016; Newton et al., 2016) .
RIPK3 signaling has been implicated in the control of diverse viral infections, including influenza A virus (IAV) , Vaccinia virus (Cho et al., 2009; Pan et al., 2014) , herpes simplex virus-1 (HSV-1) (Huang et al., 2015) , and murine cytomegalovirus (MCMV) (Upton et al., 2010 (Upton et al., , 2012 . However, evidence of death-independent, RIPK3-mediated control of viral infections remains limited. Of note, the involvement of RIPK3 in the restriction of neuroinvasive infections is not known, and studies of the role of RIPK3 in defense against potentially neuroinvasive viruses such as HSV and CMV have thus far been limited to models of peripheral infection.
West Nile virus (WNV) is an encephalitic flavivirus of global concern. WNV cycles in nature between avian and mosquito reservoirs, with incidental infection of mammals, including humans. After peripheral infection, WNV replicates in lymphoid tissues before entering the central nervous system (CNS) in a subset of human hosts. Neuroinvasive WNV infection is fatal in many patients, while survivors are often left with severe cognitive and neurologic sequelae (Sejvar et al., 2003; Vasek et al., 2016) . Neuroimmune control of WNV infection requires robust innate immune responses among resident CNS cells, as well as recruitment of infiltrating peripheral leukocytes Daniels and Klein, 2015; Suthar et al., 2013) . However, CNS immune responses must be carefully regulated, as neural tissue is susceptible to immunologic injury and is limited in its capacity for repair Wang et al., 2003) . Thus, uncovering the mechanisms that promote protective versus pathologic CNS inflammation during neurotropic flavivirus infection is critical for the development of targeted treatments, none of which currently exist (Kok, 2016) .
Here, we demonstrate a previously unknown function for RIPK3 in the coordination of protective neuroinflammation during WNV infection that is independent of MLKL-driven necroptosis. Using a mouse model of WNV encephalitis, we show that mice lacking RIPK3 or the kinase activity of RIPK1, but not those lacking MLKL or both MLKL and caspase-8, exhibit enhanced susceptibility to fatal WNV infection. While RIPK3 was dispensable for clearing WNV infection in peripheral compartments, Ripk3 À/À mice failed to effectively restrict infection within the CNS due to decreased recruitment of infiltrating leukocytes. Our studies demonstrate that RIPK3 promotes neuroinflammation during WNV infection by driving the neuronal expression of inflammatory chemokines in a manner that requires its kinase activity and that of RIPK1. These findings uncover a critical physiologic function for death-independent, RIPK3-driven inflammation in restricting a neurotropic viral infection of significant public health concern.
RESULTS

RIPK3 Restricts WNV Infection Independent of Induction of Cell Death
To assess the role of RIPK3 and MLKL in controlling WNV pathogenesis, we infected Ripk3
, and age/sex matched controls subcutaneously via footpad with 100 plaque-forming units (PFU) of the virulent WNV-TX 2002-HC strain, then monitored mice for survival and the development of clinical signs of disease. We found Ripk3 À/À mice to be highly susceptible to WNV infection, exhibiting accelerated and uniform mortality compared to congenic C57BL/6NJ (B6/N) controls ( Figure 1A ). Increased mortality in Ripk3 À/À mice was accompanied by earlier and more severe development of clinical signs of disease burden ( Figure 1B ). In contrast, survival and disease burden in mice lacking the necroptotic effector MLKL (Mlkl
) were indistinguishable from congenic C57BL/6J (B6/J) controls (Figures 1C and S1A) . A recent study of IAV pathogenesis found that upon loss of MLKL, RIPK3 signaling could alternatively mediate host defense through engagement of caspase-8-mediated apoptosis . In contrast, we found that mice lacking both MLKL and caspase-8 (Mlkl À/À Casp8 À/À ) responded similarly to littermate Mlkl À/À Casp8 +/+ controls upon WNV infection (Figures S1B and S1C). These data suggested a critical role for RIPK3 in the restriction of WNV infection that was, surprisingly, independent of MLKL-dependent programmed necrosis or caspase-8-dependent apoptosis. We next assessed whether WNV was capable of inducing RIPK3-dependent cell death in myeloid or neuronal cells, two host cell types permissive to WNV infection, by monitoring cell death via an IncuCyte imaging platform . Infection of bone marrow-derived macrophages (BMDMs) with WNV (MOI 0.01) resulted in minimal cell death in both B6/N and Ripk3 À/À BMDMs that was indistinguishable from death observed in mock-infected controls. However, WNV induced substantial cell death in the presence of the pan-caspase inhibitor zVAD in B6/N, but not Ripk3 À/À , BMDMs ( Figure 1D ), suggesting that WNV can induce RIPK3-dependent necroptosis only under conditions of caspase inhibition. In contrast, infection of primary cerebral cortical neuron cultures (MOI 0.001) resulted in modest cell death ( Figure 1D ). However, this cell death was RIPK3-independent, as WNV-induced cell death was similar in both B6/N and Ripk3 À/À cultures. Instead, WNV-induced neuronal cell death was dependent on caspase activity, as it was completely blocked in cultures of both genotypes by zVAD treatment, consistent with prior reports demonstrating WNV-induced neuronal apoptosis (Michaelis et al., 2007; Samuel et al., 2007) . Histopathologic analysis of CNS tissue sections from WT or Ripk3 À/À mice 9 days post infection (dpi) revealed no evidence for necrotic cell death in the CNS of mice of either genotype ( Figure S1D ). Together, these data indicate that, in key myeloid and CNS cell types targeted by WNV, infection alone does not trigger RIPK3-dependent cell death. Notably, while BMDMs could be induced to undergo RIPK3-dependent cell death in response to WNV infection combined with caspase inhibition, neurons were resistant to RIPK3-dependent death in these conditions. To further investigate the function of RIPK3 in controlling WNV infection, we measured viral burden in key target tissues following subcutaneous inoculation. These studies revealed transiently higher viral burden in Ripk3 À/À mice in some peripheral compartments, including serum ( Figure 1E ) and spleen (Figure 1F) , while viral burden was unchanged in draining inguinal lymph nodes ( Figure 1G ) and kidney ( Figure 1H ). Despite higher splenic and serum viral loads early after infection, Ripk3 À/À mice were nevertheless able to control infection in these compartments, with viral titers returning to levels observed in B6/N controls by 8 dpi. Peripheral immunity to WNV remained intact in Ripk3 À/À mice, which were similar to B6/N controls when comparing overall numbers and relative frequencies of all T cell and myeloid subsets analyzed in spleens on 8 dpi ( Figures  S2A-S2C ). Moreover, numbers of antigen-specific T cells identified by staining with a tetramer displaying the immunodominant WNV peptide D b -NS4B were similar between genotypes (Figure S2B ). Overall numbers of splenic B cells and serum WNVneutralizing antibody titers were also similar in Ripk3 À/À mice compared to WT controls ( Figure S2D ). Together, these data indicate that the increased pathogenesis observed in Ripk3 À/À mice after WNV infection was not due to impaired peripheral cellular immunity or a failure to control infection in peripheral compartments.
RIPK3 Is Required for Control of WNV Burden within the CNS
In contrast to our observations in peripheral tissues, we observed significantly increased viral loads in Ripk3 À/À mice across multiple CNS tissues, including cerebral cortex (Figure 2A) , brainstem ( Figure 2B ), cerebellum ( Figure 2C ), and spinal cord ( Figure 2D ). Unlike peripheral viral loads, increased CNS viral burden did not resolve to WT levels in Ripk3 À/À mice by 8 dpi. Similar to our survival studies, RIPK3-dependent control of tissue viral burden was MLKL-independent, as WNV titers were indistinguishable in Mlkl À/À mice compared to WT controls in all compartments analyzed (Figures S3A and S3B) . Combined with our observation that peripheral immunity appears intact in Ripk3 À/À mice, this finding indicates that RIPK3 may play a CNS-intrinsic role in the control of neuroinvasive WNV infection.
To test whether the protective function of RIPK3 was intrinsic to the CNS, we performed intracranial inoculation experiments, which allow examination of CNS viral replication kinetics and immune responses without possible confounding factors arising from differential neuroinvasion. While intracranial WNV infection results in 100% mortality in mice, Ripk3 À/À mice exhibited an acceleration of this mortality compared to WT controls ( Figure 2E ).
Analysis of viral burden in whole brains following intracranial inoculation revealed that WNV titers were similar between genotypes early after infection (2 dpi) ( Figure 2F ), while titers were increased in Ripk3 À/À mice compared to controls at later time points (4 and 6 dpi), suggesting that enhanced viral burden and accelerated mortality in Ripk3 À/À mice were not due to early innate control of viral replication. To reinforce this conclusion, and to test whether there might be a cell-intrinsic function of RIPK3 in controlling viral replication in target CNS cells, we performed multistep growth curve analysis of WNV replication in cultured cerebral cortical neurons and cerebellar granule cell (GC) neurons ( Figure 2G ). We observed no detectable difference in viral replication in Ripk3 À/À neurons of either type. Together, these findings indicate that RIPK3 is required to control WNV infection within the CNS, but its role is not to limit viral replication within neurons.
RIPK3 Is Required for Normal Chemokine Production in Neurons
We next questioned whether, in lieu of suppressing viral replication, RIPK3 regulated the expression of key inflammatory mediators in neurons during WNV infection. Examination of cytokine and chemokine protein levels in supernatants of in vitro B6/N and Ripk3 À/À cortical neuron cultures infected with WNV revealed no difference in the expression of the inflammatory cytokines tumor necrosis factor alpha (TNF-a) and interleukin (IL)-1b ( Figure S4A ). In contrast, Ripk3 À/À neuronal cultures exhibited decreased expression of several chemokines, including CCL2, CCL5, CCL11, CXCL1, CXCL9, and CXCL10 (Figures 3A and S4B) following WNV infection. As CCL2 and CXCL10 are both important regulators of neuroinflammation during WNV infection (Klein et al., 2005; Lim et al., 2011) , we focused subsequent investigations on these two chemokines. Subsequent qRT-PCR experiments in WNV-infected cortical neuron cultures revealed that decreased chemokine expression in Ripk3 À/À cultures was apparent at the mRNA level ( Figure 3B ), suggesting that RIPK3 promotes the transcription of inflammatory chemokines during neuronal WNV infection. Activation of RIPK3 can occur downstream of diverse toll-like receptors (TLRs), via both TRIF and Myd88-dependent pathways (He et al., 2011; Kaiser et al., 2013) . To assess whether RIPK3-driven neuronal chemokine expression was unique to WNV infection or if it could be triggered by other inflammatory stimuli, we treated primary cortical neuron cultures with the synthetic double-stranded RNA analog poly(I:C), a stimulus that activates TLR3 in neurons (Cameron et al., 2007) . These experiments revealed decreased CCL2 and CXCL10 protein ( Figure 3C ) and mRNA ( Figure 3D ) expression in Ripk3 À/À cultures compared to B6/N controls, suggesting that direct PRR stimulation was sufficient to induce RIPK3-dependent chemokine expression in the absence of active infection. Notably, we did not observe significant differences in poly(I:C)-induced expression of the inflammatory cytokines TNF-a and IL-1b in Ripk3 À/À neurons compared to B6/N controls ( Figure S4C ), consistent with our findings in WNV-infected neurons. Furthermore, we did not observe evidence for RIPK3-dependent cytokine or chemokine expression in either BMDMs or cultured microglia following treatment with TLR ligands ( Figures S4D and S4E ). Together, these findings imply that RIPK3 may have a specific role in the coordination of PRR-induced chemokine expression in neuronal lineage cells of the CNS.
To gain a more general understanding of the role of RIPK3 in coordinating neuronal chemokine expression, we assessed whether the kinase activity of RIPK3, or of its interactor RIPK1, was involved in chemokine expression downstream of additional TLR agonists, using the TLR3 agonist poly(I:C) ( Figure 3E ), the TLR4 agonist LPS ( Figure 3F ), and the TLR7 agonist CL264 ( Figure 3G ). To determine if the kinase activity of the RIP kinases was involved, we additionally treated neurons with the RIPK3 inhibitor GSK 843 or the RIPK1 inhibitor (E-G) CCL2 expression measured by ELISA in cortical neuron culture supernatants after 24 hr treatment with 1 mg/mL poly(I:C) (E), 1 mg/mL LPS (F), or 1 mg/mL CL264 (G). Prior to addition of TLR agonist, cells were pretreated for 1 hr with 30 mM Necrostatin-1 (Nec), 100 nM GSK 843, and/or 2 mM QVD. Inhibitors remained in culture medium for the duration of the experiment. As experiments in (C)-(E) happened concurrently, data with each TLR agonist is compared against a single set of vehicle controls (gray and orange bars), the data for which is repeated in each panel. n = 4 replicates/group. Necrostatin-1 (Nec) (Degterev et al., 2008) . We found that pharmacological blockade of either RIPK1 or RIPK3 resulted in suppressed CCL2 protein expression in WT neuronal cultures to levels similar to Ripk3 À/À cultures, suggesting that RIPK3-dependent chemokine expression downstream of multiple TLRs requires the kinase activity of both RIPK1 and RIPK3.
Neither inhibitor impacted CCL2 expression in Ripk3 À/À cultures, indicating that the effects of these inhibitors in WT cultures were specific to blockade of signaling through RIPK3. In contrast, CCL2 expression following treatment with the pan-caspase inhibitor QVD was not affected in either genotype, suggesting that caspase signaling is not involved in RIPK3-driven neuronal chemokine expression. Although Necrostatin-1 has been widely used to inhibit RIPK1 kinase activity, off-target effects have been reported (Takahashi et al., 2012) . We therefore repeated our Necrostatin-1 experiments using the more specific RIPK1 inhibitor GSK 963 (Berger et al., 2015) and observed very similar results ( Figure S4F ). To further establish a requirement for RIPK1 kinase activity in RIPK3-mediated neuronal chemokine expression, we generated neuronal cultures from RIPK1 kinase-dead knockin (Ripk1 KD/KD ) mice , in which an inactivating point mutation has been introduced into the catalytic domain of RIPK1. Ripk1 KD/KD neuronal cultures exhibited decreased expression of CCL2 and CXCL10 after either WNV infection ( Figure 3H ) or poly(I:C) treatment ( Figure 3I ). Consistent with a role for the kinase activity of RIPK1 in a protective chemokine response during WNV infection, Ripk1 KD/KD mice exhibited accelerated and uniform mortality ( Figure 3J ) and more severe clinical signs of disease ( Figure S4G ) compared to B6/J controls, similar to those observed in Ripk3 À/À mice, after subcutaneous infection with WNV. We next sought to confirm a role for RIPK3 in chemokine expression following TLR stimulation or WNV infection in neural cells of human origin. To do this, we tested the effect of poly(I:C) or WNV on three separate human neuroblastoma cell lines (Teitz et al., 2000) differentiated into neuron-like cells by culture in retinoic acid and brain-derived neurotropic factor (BDNF) (Encinas et al., 2000) . Upon poly(I:C) treatment or WNV infection, all three of these cell lines produced CCL2. This response was significantly reduced in all three cell lines by co-treatment with GSK 872, an inhibitor of human RIPK3 (Figure S5A) . Analogous to the results obtained with Ripk3 À/À murine neurons, inhibition of RIPK3 did not cause cell-intrinsic differences in viral growth kinetics in human neuroblastoma cells, nor did it affect cell death following WNV infection ( Figures  S5B and S5C) . Together, these studies indicate that the kinase activity of RIPK1 and RIPK3 is engaged by both TRIF and Myd88-dependent TLR signaling in neurons, that this activity drives robust neuronal chemokine expression, and that the kinase activity of RIPK1 is required for protective immunity to WNV infection.
Activation of RIPK3 in Neurons Triggers Chemokine Production, Not Cell Death
We next assessed whether direct activation of RIPK3 in the absence of any exogenous immune stimulus was sufficient to drive neuronal chemokine expression. To do this, we created mice expressing a chimeric RIPK3 protein fused to two copies of FKBP F36V (RIPK3-2xFV). The FKBP domains of this fusion protein bind with high affinity to a synthetic homolog of rapamycin referred to here as ''AP1.'' AP1 treatment induces a rapid, FKBP-mediated oligomerization of RIPK3-2xFV proteins, leading to the activation of RIPK3 and recruitment of RIPK1 in the absence of any endogenous upstream signal . For these studies, we generated mice expressing the RIPK3-2xFV construct preceded by a lox-stop-lox element and followed by a T2A-mCherry sequence, driven by the Rosa26 promoter ( Figure 4A ). These mice were crossed to mice expressing Cre recombinase under the ubiquitously expressed Meox2 (Mox2) promoter, resulting in Cre-mediated excision of the inserted stop codon ( Figure 4B ). Transgene expression was confirmed in primary murine embryonic fibroblasts (MEFs) via western blot for FKBP ( Figure 4C ) and fluorescent immunocytochemical detection of mCherry ( Figure 4D ). Similar to our previous studies using a related construct in NIH 3T3 cells Yatim et al., 2015) , AP1 treatment of RIPK3-2xFV expressing primary MEFs resulted in robust cell death and chemokine expression in Mox2-Cre + cultures ( Figures 4E and 4F Figure 4H ). However, AP1 treatment did potently induce chemokine expression in RIPK3-2xFV + Mox2-Cre + neurons in a manner that required the kinase activity of RIPK3, as the RIPK3 inhibitor GSK 843 blocked AP1-mediated neuronal chemokine expression ( Figure 4I ). We previously demonstrated that RIPK3 oligomerization triggers the recruitment and activation of RIPK1. Consistent with these findings, and with a role for the kinase activity of RIPK1 in the observed chemokine production, we found that co-treatment with the RIPK1 inhibitor Nec1 also abrogated AP1-induced chemokine expression in RIPK3-2xFV + Mox2-Cre + neurons. These data indicate that direct activation of RIPK3 alone is sufficient to induce death-independent chemokine expression in neurons.
RIPK3 Is Required for Normal Chemokine Production in the CNS upon WNV Infection
To confirm that RIPK3 contributed to CNS chemokine expression in vivo, we analyzed brain homogenates from WT and Ripk3 À/À mice following either subcutaneous or intracranial WNV infection. Consistent with our in vitro results using neuronal cultures, brains of Ripk3 À/À mice exhibited decreased CCL2 and CXCL10 expression compared to B6/N controls following both subcutaneous ( Figure 5A ) and intracranial ( Figure 5B ) infection. Additional experiments revealed that CCL2 and CXCL10 mRNA levels were similarly decreased in Ripk3 À/À brains in both infection models ( Figures 5C and 5D ). Brains of WNV-infected Ripk3 À/À mice exhibited decreased expression of additional chemokines, including CCL11, CXCL1, and CXCL9, although the impact of RIPK3 on expression of these additional chemokines was variable between infection routes ( Figures  S6A and S6B ). In contrast, brains of Mlkl À/À mice exhibited levels of chemokine expression after subcutaneous WNV infection that were indistinguishable from B6/J controls ( Figure S6C ).
RIPK3 Coordinates Immune Cell Infiltration into the CNS upon WNV Infection
As mice lacking RIPK3 exhibited diminished expression of leukocyte chemoattractants in the CNS during WNV infection, we questioned whether this would result in poor CNS recruitment of inflammatory cells. Flow cytometric analysis of leukocytes isolated from whole brains at 8 dpi following subcutaneous inoculation revealed significantly decreased recruitment of multiple subsets of infiltrating cells in the CNS of Ripk3 À/À mice, including CD4 + and CD8 + T cells ( Figures 6A and 6B) . Notably, Ripk3
À/À mice were also impaired in their ability to recruit antigen-specific CD8 + T cells to the CNS, exhibiting both decreased relative percentages and overall numbers of WNV-NS4B tetramer + CD8 + cells ( Figures 6C and 6D) . Analysis of infiltrating myeloid cell Figure 7C ). We also observed decreased numbers of CD45 hi CD11b + F4/80 + CCR2 + inflammatory monocytes ( Figure 7D ). Whole brain homogenates also exhibited decreased mRNA expression of both CXCR3 and CCR2 ( Figure 7E ). While some of this chemokine receptor expression is derived from resident CNS cells, these data support the notion of decreased CXCR3 and CCR2 expressing infiltrating cells in the brains of Ripk3
mice. Ultimately, these findings suggest that RIPK3-dependent expression of CXCL10 and CCL2 is necessary for robust recruitment of antiviral leukocytes to the CNS during WNV infection.
DISCUSSION
Despite their profound and growing burden to global public health, the factors that govern pathogenesis and host control of neurotropic infections remain incompletely understood.
Here, we demonstrate a previously unknown function for RIPK3 in coordinating protective neuroinflammation during neuroinvasive WNV infection. Remarkably, RIPK3 restricted WNV pathogenesis in a necroptosis-independent manner, as WNV did not induce necroptosis in primary neuronal cultures and both MLKL and caspase-8 were dispensable for the protective effects of RIPK3 in vivo. While RIPK3 did not directly influence viral replication within neurons, it was necessary for robust neuronal chemokine expression and the CNS recruitment of infiltrating antiviral leukocytes, an effect that also required the kinase activity of RIPK1. These findings identify RIPK3 as a key neuronal regulator of CNS inflammation during flavivirus encephalitis. In vivo neuronal expression of RIPK3 has been established by several recent reports and appears to contribute to inflammation and pathogenesis in rodent models of cerebral ischemia/reperfusion injury (Xu et al., 2016) , lysosomal storage disorders (Vitner et al., 2014) , and traumatic brain injury (Liu et al., 2016) . RIPK3 is also expressed in glia, including microglia, astrocytes, and oligodendrocytes, where it has been shown to contribute to the pathogenesis of rodent and human neurodegeneration, CNS autoimmunity, and demyelination (Ito et al., 2016; Ofengeim et al., 2015; Re et al., 2014) . While the potential for RIPK3 to induce neuroinflammatory pathogenesis has been well established by these prior reports, our study instead demonstrates an indispensable, protective role for RIPK3-mediated neuroinflammation and establishes RIPK3 as a critical host factor in controlling neurotropic viral infection. Our study focused on RIPK3-dependent effects in neurons, as they are the primary CNS target of WNV and exhibit robust chemokine expression during infection (Getts et al., 2008; Klein et al., 2005) . While we did not observe a requirement for RIPK3 signaling in chemokine production by microglia, our results cannot rule out additional roles for this pathway in non-neuronal cells of the CNS. We also note efforts that are currently underway to develop RIPK1 inhibitors with activity in the CNS as a treatment for neurodegeneration and ischemic injury. Our findings indicate that such compounds may also increase susceptibility to neuroinvasive viral infection.
A key finding in our study is the contribution of RIPK3 to the chemotactic milieu that supports protective antiviral neuroinflammation. Neuronal expression of chemokines has been well established to underlie successful antiviral immunity during WNV infection, contributing to leukocyte influx and viral clearance (Bardina et al., 2015; Durrant et al., 2015; Klein et al., 2005) . Beyond the context of infection, CNS chemokines also serve critical roles in CNS homeostasis, development, neurotransmission, and repair (Durrant et al., 2014b; Ransohoff and (E) qRT-PCR analysis of CXCR3 or CCR2 expression using RNA extracted from whole brains on day 8 following subcutaneous WNV infection. **p < 0.01, ***p < 0.001. All data are pooled from two independent experiments. Trettel, 2015; Ré aux-Le Goazigo et al., 2013; Williams et al., 2014a) . Our findings raise the additional possibility that RIPK3 may serve previously unknown chemokine-mediated functions in a diverse array of neurologic processes. Our study and other reports (Lawlor et al., 2015; Moriwaki and Chan, 2016; Najjar et al., 2016; Newton et al., 2016; Wang et al., 2014b ) demonstrate a capacity for RIPK3 to induce inflammation independently of necroptosis. While recent studies have demonstrated a death-independent role for RIPK3 in NLRP3 inflammasome activation (Lawlor et al., 2015; Wang et al., 2014b) as well as noncanonical IL-1b processing in myeloid cells (Moriwaki et al., 2015) , our study did not uncover any impact on IL-1b mRNA or protein expression in Ripk3 À/À neuronal cultures or brain tissues following WNV infection. Moreover, the phenotype of Ripk3 À/À mice following WNV infection is markedly different than mice lacking the IL-1 receptor or the inflammasome adaptor ASC, which both exhibit elevated CNS chemokine expression and enhanced, but not protective, neuroinflammation (Durrant et al., 2013 Kumar et al., 2013; Ramos et al., 2012) . Thus, death-independent functions for RIPK3 may differ significantly by inflammatory stimulus and host cell type. Consistent with this idea, we found that in neurons, but not in bone marrow-derived myeloid cells or microglia, chemokine expression stimulated by TLR agonists or WNV infection required the kinase activity of both RIPK1 and RIPK3. Also consistent with this finding, mice expressing a kinase-dead form of RIPK1 displayed increased susceptibility to WNV infection similar to that observed in Ripk3 À/À mice. We also found that even direct activation of RIPK3 in neurons failed to trigger necroptosis, but rather promoted chemokine expression. Further molecular mechanisms that govern the functions of RIPK1 and RIPK3 in these contexts remain the subject of ongoing investigation, though our study provides some initial insights. For example, in contrast with recent reports using cultured myeloid cells (Ito et al., 2016) , in neurons we observed that the requirement for RIPK1 and RIPK3 kinase activity downstream of TLR ligation did not require inhibition of the caspases. While we report an unexpected requirement for RIPK1 and RIPK3 signaling downstream of TLR ligation in neurons, our findings do not rule out engagement of RIPK signaling by other innate immune pathways during WNV infection of these cells. Together, our findings indicate an unexpected diversity in the outcomes of RIPK1 and RIPK3 signaling between cell types and imply additional obligate functions for this pathway within the CNS that are not observed in other tissues.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice Ripk3 À/À (Newton et al., 2004) , Mlkl À/À (Murphy et al., 2013) , Casp8 À/À (Beisner et al., 2005) , , and RIPK3-2xFV fl/fl Mox2-Cre + mice in this study were bred and housed under specific-pathogen free conditions at the University of Washington. Wild-type C57BL/6NJ and C57BL/6J controls were either obtained commercially (Jackson Laboratories) or bred in-house. Ripk3 À/À animals were congenic to the C57BL/6NJ background, while all other strains were on the C57BL/6J background; in all cases wild-type controls of appropriate sub-strain were used. Mox2-Cre + mice were obtained commercially (Jackson Laboratories, strain 003755) and maintained at hemizygosity. RIPK3-2xFV fl/À mice were produced for the authors by inGenious
Targeting Laboratory (Rankonkoma, NY). RIPK3-2xFV fl/fl mice were generated using a vector containing a FLAG tag, followed by a chimeric version of RIPK3 fused to two copies of FKBP F36V (RIPK3-2xFV), followed by a T2A-mCherry sequence ( Figure S5A ). This entire sequence was cloned into the MluI site of a ROSA26-stop backbone vector using conventional cloning methods. The stop cassette in the ROSA-stop backbone vector contains a splice acceptor and a stop cassette flanked by lox-p sites and is inserted in intron 1 of the Rosa26 locus. The FLAG-RIPK3-T2A-mCherry sequence is inserted immediately downstream of the stop cassette. Genotyping of the RIPK3-2xFV transgene and confirmation of a deleted stop cassette was accomplished using multiple PCR reactions ( Figure 4B ). Two separate reactions were used to detect the presence of the RIPK3-2xFV transgene (349bp product) and the transgene with a deleted stop cassette (603bp product). Homozygosity of the transgene was assessed by confirming the absence of a WT Rosa26 locus (346bp product). Mox2-Cre expression was confirmed by the presence of a mutant (300bp) product Table S1 for primer sequences. PCR reactions were performed with EconoTaq reagents (Lucigen) using genomic DNA extracted from ear tissue according to standard protocols.
Cell culture and infections
Primary macrophage cultures were generated from bone marrow via differentiation in 40 ng/ml M-CSF, as described . Embryonic fibroblasts were generated and maintained as previously described . Primary cultures of cerebral cortical neurons and purified cerebellar granule cell neurons were generated using E15 embryos or P3 neonatal mice, as described (Klein et al., 2005) . Purified microglia were obtained from mixed glial cultures generated from P1-P3 neonatal mice as described . Human neuroblastoma cell lines NB8, NB15, NB16 were maintained in a 1:1 mixture of DMEM and Ham's F-12 Nutrient Mix (ThermoFisher). Neuroblastoma cells were differentiated into neuron-like cells by supplementing culture medium with 10 mM all-trans retinoic acid (Sigma-Aldrich) and 50ng/ml recombinant human BDNF (Peprotech), as described (Encinas et al., 2000) . For infection experiments, macrophage cultures were infected at MOI 0.01, while primary neuronal cultures and neuroblastoma cell lines were infected at MOI 0.001.
